Call for Editor-in-Chief of Expert Review of Hematology

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Call for Editor-in-Chief

Expert Review of Hematology

29 January 2021

About the role

Expert Review of Hematology (2019 Impact Factor: 2.573) is currently looking for its first Editor-in-Chief with an academic background in hematology, as well as the passion to drive the journal forward in an exciting period of change and growth. It is a significant role with a high profile, but one that is achievable within a busy working academic timetable.

The journal is part of Taylor & Francis’ Expert Collection and provides commentary and analysis to elucidate best clinical practice in hematology and to translate advances in all areas of hematology research. We publish reviews, original research, editorials, and drug profiles, which ensure coverage of all aspects of hematology including hematological malignancies, blood disorders, stem cell transplantation, and transfusion medicine. 

The successful candidate will spearhead the editorial board and work closely with the Commissioning Editor and Portfolio Manager on a regular basis. She/he will regularly advise the commissioning editor in ensuring the most relevant and up-to-date content is commissioned and covered in the journal as well as representing the journal at conferences and networking events, where possible. From time to time, the Commissioning Editor may also request the Editor-in-Chief’s support in making final decisions on manuscripts that require further review.

The Expert Collection journals commission expert authors who have a publication record of at least 100 papers in total, of which 50 are within their area of expertise. The successful candidate will meet or exceed this publication record and will regularly submit to the journal, when possible.

Taylor & Francis will organise regular board meetings, and we will supply annual reports reflecting on the performance of the journal. The journal utilises an online editorial office system, ScholarOne, in which training can be provided if needed.

Becoming the editor of a journal is a rewarding and fulfilling experience where you will build your own networks, promote the research that you are passionate about, and be recognized as a leading figure within the academic community.

Interested in applying? Here are the skills and attributes we would be looking for in a successful applicant:

  • Someone who is active in the hematology community with strong personal networks and a publication record of at least 100 published papers
  • Confidence to engage with authors and researchers to solicit the highest quality submissions on behalf of the journal
  • The ability to foster positive working relationships with the journal’s Commissioning Editor and Portfolio Manager
  • Regularly available and proactive in advising the Commissioning Editor of topics and areas of research to commission for the journal in order to increase readership
  • Willing to provide feedback, guidance, and support in the journal’s development and growth on a regular basis
  • A regular attendee/speaker at hematology conferences and willing to represent the journal at meetings and events


The role will formally begin in September/ October.


Submitting your Application

If you would like to apply for the position of Editor-in-Chief, please forward your CV, a covering letter, and a vision statement to Mithi Ahmed, Commissioning Editor, and Alexa Josaphouitch, Portfolio Manager. Your vision statement should be no longer than two pages and should cover:

  • Where you believe the field is going, and the journal’s place within it
  • How you would work in partnership with the editorial board
  • How you would maintain and increase the quality of submissions
  • How you would work with authors

A MEDLINE-indexed journal providing commentary and analysis to elucidate best clinical practice in hematology. While translating advances in immunology, stem cell, and cell and gene therapy research into the clinical context. It offers accelerated publication.